China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a strategic partnership with fellow Chinese firm Nanjing Zenshine Pharmaceuticals Co., Ltd. The agreement grants Jumpcan exclusive promotion rights to Zenshine’s polymerase acidic (PA) inhibitor, ZX-7101A, for the agreed indication in China mainland.
Financial Terms and Promotion Rights
In exchange for the exclusive promotion rights, Jumpcan will pay Zenshine a total of RMB120 million as promotion consideration, which includes an upfront payment of RMB50 million and a milestone payment of RMB70 million. Additionally, Jumpcan will make an RMB60 million equity investment in Zenshine. Zenshine, in turn, will pay Jumpcan a sales-based double-digit promotion service fee.
ZX-7101A: A Promising Broad-Spectrum Anti-Influenza Drug
ZX-7101A is an RNA PA inhibitor developed by Zenshine that exhibits broad-spectrum anti-influenza virus properties, effectively suppressing both influenza A and B viruses, including highly lethal avian influenza viruses. The drug has completed a Phase I/II study in China, with primary endpoints indicating that all dose groups of ZX-7101A significantly reduced the time required for influenza symptom relief compared to the control group, demonstrating significant statistical differences.
Clinical Efficacy and Symptom Relief
The secondary clinical endpoint revealed a significant reduction in the median response time for four systemic symptoms—muscle or joint pain, fatigue, headache, fever, or aversion to cold/sweating—and three respiratory symptoms—nasal congestion, sore throat, and cough. These results highlight the potential of ZX-7101A as an effective treatment for influenza.-Fineline Info & Tech
